Hot topics | Coronavirus pandemic

Global Liquid Biopsy Market Research Report 2022: Research versus Clinical Liquid Biopsy / Liquid Biopsy Market by Type of Analyte

Global Liquid Biopsy Market Research Report 2022: Research versus Clinical Liquid Biopsy / Liquid Biopsy Market by Type of Analyte

DUBLIN, Jan. 14, 2022 /PRNewswire/ -- A new report has been added to ResearchAndMarkets.com's offering.

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks, limitations, and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology as an alternative or complementary method to the current standards of care.

This report contains up-to-date information and important data points for business planning.

  • Research vs. Clinical Liquid Biopsy
  • The Market for Liquid Biopsy by Region
  • The Market for Liquid Biopsy Market by Type of Analyte
  • The Market for CTC-based Liquid Biopsy
  • The Market for ctDNA-based Liquid Biopsy
  • The Market for EV and Exosome-based Liquid Biopsy
  • The Market for Multi-Analyte-based Liquid Biopsy
  • The Market for Other Liquid Biopsy
  • Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

Liquid biopsy testing has a range of possibilities in a range of aspects of clinical oncology, including:

  • Early detection and diagnosis/screening
  • Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • Prognosis of disease

Key Topics Covered:

THE SUMMARYINTRODUCTIONLIQUID BIOPSY TECHNOLOGIESINDUSTRY STRUCTURELIQUID BIOPSY MARKET REVENUES AND FORECAST

TECHNOLOGIES IN THE LIQUID BIOPSY CHAPTER 2

CHAPTER 3: ACCULATING TUMOR DNA (CTDNA) LIQUID BIOPSYINTRODUCTIONADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSYCURRENT CTDNA-BASED LIQUID BIOPSY TESTS

  • Biocartis
  • Biocept
  • Biodesix
  • CellMax Life
  • Circulogene
  • Diacarta
  • Epigenomics
  • Foundation Medicine (Roche)
  • Guardant Health
  • Inivata (Neogenomics)
  • LungLife AI
  • Myriad Genetics
  • NeoGenomics
  • OncoDNA
  • Personal Genomic Diagnostics
  • QIAGEN
  • Resolution Biosciences
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus

IN REVELOPMENT, CTDNA-BASED LIQUID BIOPSY TESTS

  • Exact Sciences
  • Freenome
  • GRAIL
  • Neogenomics

CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSYINTRODUCTIONCHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTSCTC-BASED LIQUID BIOPSY TESTS

  • Adaptive Biotechnologies
  • Biocept
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN

TESTS IN THE MARTIN WORK TO CTC-BASED LIQUID BIOPSY

ANGLEEpic SciencesLiquid Biotech USA

EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSYINTRODUCTIONLIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES/OTHER ANALYTES

  • Aspira Women's Health (formerly Vermillion)
  • Biodesix
  • Exosome Diagnostics
  • Hologic
  • MDxHealth

EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT

  • Circulogene
  • OncoCyte
  • Resolution Biosciences
  • VolitionRx

TESTSLIQUID BIOPSY TESTS IN MULTIPLE ANALYTES IN CHAPTER 6

  • Biocept
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA

TESTS OF REAL TIME ANALYTE-BASED LIQUID BIOPSY IN DEVELOPMENT

  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

LIQUID BIOPSY TESTS FOR RESEARCH USE ONLYINTRODUCTIONLIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

  • Agena Bioscience
  • ANGLE
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • Natera
  • QIAGEN

THE ANALYSISTIERS OF COMPETITIONCOMPETIVE FACTORSSIGNIFICANT MARKET TRENDS IN CHAPTER 8

  • Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers

NO LONGER IN THE LIQUID BIOPSY MARKET IN COMPETITORS

THE LIVING BIOPSY MARKET IN OVERVIEWMARKET FORECE CHAPTER 9

CHAPTER 10: MARKET BY ANALYTE CIRCULATING TUMOR DNA

CIRCULATING TUMOR CELLSEXTRACELLULAR VESICLES AND OTHER ANALYTESMULTIPLE ANALYTES

  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast

PROGNOSIS FOR MONITORINGDIAGNOSIS/SCREENINGDISEASE PROGNOSIS IN CHAPTER 11

  • Market Overview
  • Revenue Forecast

CHAPTER 12: MARKET BY CANCER TYPEBREAST CANCERCOLORECTAL CANCERPROSTATE CANCEROTHER CANCERS: Including bladder, gastrointestinal, pancreatic, renal, and melanoma and hematological malignancies

  • Market Overview
  • Revenue Forecast

TESTS OF PAN-CANCER

  • Market Overview
  • Revenue Forecast

PROFILESTOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET TERMINATORY STATE

Mentioned by companies

  • Adaptive Biotechnologies
  • Agena Bioscience, Inc.
  • Angle, plc
  • Aspira Women'S Health
  • Biocartis Group Nv
  • Biocept, Inc.
  • Biodesix
  • Cellmax Life
  • Circulogene
  • Diacarta, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc. (Roche)
  • Freenome, Inc.
  • Gilupi GmbH
  • Grail (Illumina)
  • Guardant Health, Inc.
  • Hologic
  • Lunglife Ai (Formerly Cynvenio Biosystems)
  • Mdxhealth
  • Menarini-Silicon Biosystems, Spa
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Neogenomics Laboratories, Inc.
  • Oncocyte Corporation
  • Oncodna S.A.
  • Oncimmune
  • Personal Genome Diagnostics
  • Predicineq2 Solutionsqiagen N.V.
  • Cell-Free Dna Technologies
  • Ctc Technologies
  • Exosome and Mirna Technologies
  • Resolution Biosciences (Agilent)
  • Roche Diagnostics
  • Stagezero Life Sciences
  • Sysmex-Inostics, Inc.
  • Tempus
  • Veracyte
  • Volitionrx

For more information on this report, visit the National Geographic Portal.

Contactation avec les medias:

Laura Wood, Senior Manager for E.S.T Office Hours Call +1-917-300-0470 For GMT Office Hours Call +353-1-416-8900 Fax: 646-607-1907 Fax (outside United States): +353-1-481-1716

SOURCE Research and Markets

You may also like: